Based on their analysis, the researchers compiled a recommended number of genes to include in panels for 14 cancer types.
Aiming to better select panels and models for accurate prediction of tumor mutational burden (TMB), researchers are proposing cancer-specific panels for an array of malignancies, which they say can help better select the appropriate patients for immune checkpoint inhibitor treatment.
The researchers analyzed the prevalence of mutations across the cancers, finding high variability.
“In view of the significant variability among different types of tumor, a cancer-specific strategy was used to design panels for TMB prediction,” wrote the researchers, “After excluding the largest genes, we selected for each cancer type the genes with mutations in ≥1% of the samples. Samples with mutations in at least one of these ‘gene-sets’ were used for further analysis.”
Based on their analysis, the researchers compiled a recommended number of genes to include in panels for each of the cancer types:
The proportion of genes that overlapped in the panels for the different cancer types ranged from 0% to 40%. In some cases, such as urinary tract or non-melanoma skin tumor, the percentage never reached 10%.
In order to test the association of the TMBs estimated in each of the recommended panels with outcomes to immune checkpoint inhibitor treatment, the researchers drew on data from a published cohort of 174 patients with metastatic melanoma and a cohort of 34 patients with NSCLC.
“First, we predicted the TMB for each sample using our suggested panels of 126 genes (0.79 Mb) for melanoma and 175 genes (0.97Mb) for NSCLC. As expected, predicted TMBs showed an excellent correlation with the published, experimental TMBs (R2=0.96 and 0.84 for melanoma and lung, respectively),” explained the researchers.
In their analysis, they found that a threshold of 150 mutations showed the best correlation with response to treatment. “Response rate of melanoma patients with >150 predicted mutations was 51%, compared with 18% in those with <150 predicted mutations.”
Median overall survival (OS) among patients with high predicted TMB was 24.3 months, more than double that of patients with low predicted TMB, who had an OS of 10.1 months.
The researchers found similar results when looking at the NSCLC cohort, with 56% of patients with high predicted TMB achieving a partial response to TCB treatment compared with 175 of patients with low TMB.
Reference
Martínez-PérezE, Molina-Vila M, Marino, Buslje C. Panels and models for accurate prediction of tumor mutation burden in tumor samples. NPJ Precis Oncol. Published online April 13, 2021. doi:10.1038/s41698-021-00169-0
NK Cell Therapy SNK01 Improves Cognitive Function in Alzheimer Disease for up to 11 Weeks
December 3rd 2023Among 10 patients evaluated, compared with their baseline at 1 week after receiving their final dose in the trial, 30% demonstrated clinical improvement on the Alzheimer’s disease composite score.
Read More
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More